A Phase 2 Study of BA3011 Alone and in Combination With PD-1 Inhibitor in Adult Patients With Metastatic Non-small Cell Lung Cancer (NSCLC) Who Had Prior Disease Progression on a PD-1/L-1 Inhibitor

Grants and Contracts Details

StatusActive
Effective start/end date9/14/215/2/23

Funding

  • Labcorp Drug Development Incorporated: $21,631.00